Trial Profile
Interventional, Open-label, Two Single Dose, Fixed-sequence Study Investigating the Absorption, Metabolism and Excretion (AME) of Idalopirdine Following a Single Oral Dose of Lu AF67708 ([Ethyl-1-14C]-Idalopirdine) and Lu AF67709 ([Benzyl-7-14C]-Idalopirdine) in Healthy Men
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Jul 2015
Price :
$35
*
At a glance
- Drugs Idalopirdine (Primary)
- Indications Alzheimer's disease; Cognition disorders
- Focus Pharmacokinetics
- Sponsors Lundbeck A/S
- 17 Jul 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 18 Apr 2015 New trial record